Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S278400
Reexamination Certificate
active
07345063
ABSTRACT:
The invention provides compounds of general formula (I), wherein R1, X, Y, n, R2, Z1, Z2, A1, A2, Q, R3, R4, R5, R6, R7, R8, t and R16are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
REFERENCES:
patent: 3203992 (1965-08-01), Kunz et al.
patent: 3577432 (1971-05-01), Helsley et al.
patent: 3755584 (1973-08-01), Plotnikoff et al.
patent: 3818017 (1974-06-01), Janssen et al.
patent: 3894030 (1975-07-01), Janssen et al.
patent: 4029801 (1977-06-01), Cavalla et al.
patent: 4080328 (1978-03-01), Maruyama et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4264613 (1981-04-01), Regnier et al.
patent: 4304915 (1981-12-01), Berthold
patent: 4338323 (1982-07-01), Regnier et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 37 23 568 (1989-01-01), None
patent: 37 23 648 (1989-01-01), None
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-03-01), None
patent: 2 190 430 (1974-02-01), None
patent: 1368012 (1974-09-01), None
patent: WO93/25528 (1993-12-01), None
patent: WO97/23458 (1997-07-01), None
patent: WO98/32442 (1998-07-01), None
patent: WO99/25686 (1999-05-01), None
patent: WO99/31092 (1999-06-01), None
patent: WO99/65895 (1999-12-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/58305 (2000-10-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/43744 (2001-06-01), None
patent: WO 01/44227 (2001-06-01), None
patent: WO 01/87839 (2001-11-01), None
Barnes et al., “Prospects fornew drugs, etc.,” Lancet 2004; 364, pp. 985-996.
Barnes, “COPD: is there light at the end of the tunnel?”, Current Opinion in Pharmacology 2004, 4: 263-272.
de Boer, “Potential new drugs for therapy, etc.,” Expert. Opin. Investig. Drugs (2003) 12(7): 1067-1086.
U.S. Appl. No. 10/204,754 filed Aug. 23, 2002, Hansen et al.
U.S. Appl. No. 10/204,789, filed Aug. 23, 2002, Hansen et al.
U.S. Appl. No. 10/204,790, filed Aug. 23, 2002, Bodkin et al.
U.S. Appl. No. 10/311,667, filed Dec. 17, 2002, Eriksson et al.
U.S. Appl. No. 10/311,841, filed Dec. 17, 2002, Eriksson et al.
U.S. Appl. No. 10/468,179, filed Aug. 18, 2003, Brough et al.
U.S. Appl. No. 10/472,412, filed Sep. 16, 2003, Eriksson et al.
Archibald et al., “Antiinflammatory 4-acylaminopiperidines”,CAPLUS77:34355 (1972).
Cattanach et al., “Studies in the Indole Series. Part IV. Tetrahydro-1H-pyrido[4, 3-b]-indoles as Serotonin Antagonists”,J. Chem. Soc. C. 10:1235-1243 (1968).
Cohen et al., “Cytokine function: A study in biologic diversity”,CAPLUS125:31527 (1996).
Friebe et al., “Piperidinopropyl derivatives and pharmaceutical compositions containing them”,CAPLUS94:103172 (1981).
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,J. Biol. Chem.273(25):15687-15692 (1998).
Howard et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents”,Trends in Biotechnology14:46-51 (1996).
Manabu Hori Kim D. Janda, “A Soluble Polymer Approach to the “Fishing Out” Principle: Synthesis and Purification of β-Amino Alcohols”,J. Org. Chem.63:889-894 (1998).
Komai et al., “Structure-Activity Relationships of HIV-1 PR Inhibitors Containing AHPBA-II. Modification of Pyrrolidine Ring at P1′ Proline”,Bioorganic&Medicinal Chemistry4(8):1365-1377 (1996).
Leclerc et al., “Derivatives Related to Betaxolol with I-and J-Adrenergic Activities”,Arzneim.-Forsch/Drug. Res.35(11):1357-1367 (1985).
Meurer et al., “Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection—II.”,CAPLUS2000:331722 (2000).
Navas III et al., “The Design and Synthesis of a Hapten for 1192U90, A Potential Atypical Antipsychotic Agent”,Synthetic Communications26(7):1411-1421 (1996).
Payard et al., “N-Aminomethylated Derivatives of Some Hydroxamic Acids as Anti-Inflammatories”,Eur. J. Med. Chem.pp. 1-10 (1975).
Rubini et al., “Synthesis of Isosteric Methylene-Oxy Pseudodipeptide Analogues as Novel Amide Bond Surrogate Units”,Tetrahedron42(21):6039-6045 (1986).
STN Int'l,CAPLUS1968.402884.
Timmermans et al., “Hypotensive Properties of Benzodioxane Derivatives Structurally Related to R 28935. Comparison of Activity with some Receptor Affinities”,Arch. int. Pharmacodyn.255:321-334 (1982).
Wright et al., “Discovery of Selective Dopamine D4 Receptor Antagonists: 1-Aryloxy-3-(4-Aryloxypiperidinyl)-2-Propanols”,Bioorganic&Medicinal Chemistry Letters7(11):1377-1380 (1997).
Alcaraz et al., “Preparation of piperidinyl alcohols as chemokine receptor modulators for treatment of diseases such as asthma”,CAPLUS139:197375 (2003).
Bechtloff et al., “Pseudopolymorphs in industrial use”,SciSearch10289666 (2001).
Berthold, “3-Aminopropoxyaryl derivatives”,CAPLUS93:8015 (1980).
Black et al., “Increased chemical purity using a hydrate”, SciSearch 12765805 (2004).
Chou et al., “Adrenergic regulation of macrophage-derived tumor necrosis factor-α generation during a chronic polyarthritus pain model”,CAPLUS129:3784 (1998).
Eriksson et al., “Preparation of benzimidazol derivatives as modulators of chemokine receptors”,CAPLUS137:2476987 (2002).
Exhibit A CAS search result.
Hu et al., “Dependence of the chemical dynamics of intercluster association reactions on the strength of the solute-solvent intermolecular potential”,Beilstein Abs.5809171 (1993).
Katritsky et al., “Heterocyclic Chemistry”, Cambridge, p. 75 (1964).
Levine, “β2-Andrenergic mechanisms in experimental arthritis”,CAPLUS109:25680 (1988).
Matsuo et al., “Preparation of N-pentadienoylaminoalkyl-4-(3-indolyl) piperidines and analogs as antiallergic agents”,CAPLUS155:232091 (1991).
Mizuhashi, “A guinea pig model of propranolol-induced bronchoconstriction (PIB) after allergic immediate asthmatic reaction and the role of thromboxane A2 and 5-lipoxygenase products”,CAPLUS122:717129 (1995).
Saeki, “Moleclar mechanism of rheumatoid arthritus and relationship between cytokine and chronic rheumatoid arthritus”,CAPLUS125:272100 (1996).
Schmidt et l., “Molecular mechanism in allergy and clinical immunology”,J Allergy Clin Immunol105:673-682 (2000).
Tanabe et al., “Propanol derivatives as antihypertensives”,CAPLUS96:110143 (1982).
Tanaka et al., “Antiallergic effects of a novel compound, SWR-00151”,CAPLUS126:311929 (1997).
Wright et al., “Subtype-Selective N-Methyl-D-Aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Heteroarylalkynl)-4-benzylpiperidines”,CAPLUS133:321781 (2000).
Yamamoto, “Expression of monocyte chemotactic by cross-linked dimerization of a ribosomal protein”,CAPLUS127::64176 (1997).
Zenitz et al., “3-(Piperidino-lower-alkyl) indoles”,CAPLUS87:102164 (1977).
Eriksson Tomas
Lawitz Karolina
Astrazeneca AB
Fish & Richardson P.C.
Morris Patricia L.
LandOfFree
Amides, preparation and therapeutic use as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amides, preparation and therapeutic use as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amides, preparation and therapeutic use as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2804719